ArticleBritish journal of clinical pharmacology2019
Handling interoccasion variability in model-based dose individualization using therapeutic drug monitoring data.
Article in British journal of clinical pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- Accelerating tacrolimus model-informed precision dosing in kidney transplant recipients: Model evaluation and refinement strategies.British journal of clinical pharmacology · 2026Pooled it
- Published Population Pharmacokinetic Models of Imatinib Perform Poorly on TDM Data from Pediatric Patients.Targeted oncology · 2025Pooled it
- Time-varying voriconazole clearance during extracorporeal membrane oxygenation.Antimicrobial agents and chemotherapy · 2026Observational
- The Rational Basis for Personalized Treatment Using Concentration-Guided Dosing.Therapeutic drug monitoring · 2025Review
- Interoccasion variability in population pharmacokinetic models: identifiability, influence, interdependencies and derived study design recommendations.Journal of pharmacokinetics and pharmacodynamics · 2025Article
- Recommended approaches for integration of population pharmacokinetic modelling with precision dosing in clinical practice.British journal of clinical pharmacology · 2025Review
- Drug-drug interaction of paroxetine on olanzapine and initial dosage optimization in patients with major depressive disorder based on population pharmacokinetics.Frontiers in psychiatry · 2025Article
- External validation of population pharmacokinetic models of tacrolimus in Thai adult liver transplant recipients.European journal of clinical pharmacology · 2024Article
- Pharmacogenetic Testing or Therapeutic Drug Monitoring: A Quantitative Framework.Clinical pharmacokinetics · 2024Article
- A Population Pharmacokinetic Study to Compare a Novel Empagliflozin L-Proline Formulation with Its Conventional Formulation in Healthy Subjects.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Model-Informed Precision Dosing to Reduce Vincristine-Induced Peripheral Neuropathy in Pediatric Patients: A Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis.Clinical pharmacokinetics · 2024Article
- Guiding the starting dose of the once-daily formulation of tacrolimus in "Frontiers in pharmacology · 2024Article
- Tutorial on model selection and validation of model input into precision dosing software for model-informed precision dosing.CPT: pharmacometrics & systems pharmacology · 2023Article
- Towards Model-Informed Precision Dosing of Voriconazole: Challenging Published Voriconazole Nonlinear Mixed-Effects Models with Real-World Clinical Data.Clinical pharmacokinetics · 2023Article
- Adaptation of a population pharmacokinetic model to inform tacrolimus therapy in heart transplant recipients.British journal of clinical pharmacology · 2023Article
- Simulating clinical trials for model-informed precision dosing: using warfarin treatment as a use case.Frontiers in pharmacology · 2023Article
- Individualized Patient Care Through Model-Informed Precision Dosing: Reflections on Training Future Practitioners.The AAPS journal · 2022Article
- Implementation and Cross-Validation of a Pharmacokinetic Model for Precision Dosing of Busulfan in Hematopoietic Stem Cell Transplanted Children.Pharmaceutics · 2022Article
- Cefepime Precision Dosing Tool: from Standard to Precise Dose Using Nonparametric Population Pharmacokinetics.Antimicrobial agents and chemotherapy · 2022Article
- Evaluation of two software using Bayesian methods for monitoring exposure and dosing once-daily intravenous busulfan in paediatric patients receiving haematopoietic stem cell transplantation.Cancer chemotherapy and pharmacology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThis study aims to assess approaches to handle interoccasion variability (IOV) in a model-based therapeutic drug monitoring (TDM) context, using a population pharmacokinetic model of coagulation factor VIII as example.
methodsWe assessed 5 model-based TDM approaches: empirical Bayes estimates (EBEs) from a model including IOV, with individualized doses calculated based on individual parameters either (i) including or (ii) excluding variability related to IOV; and EBEs from a model excluding IOV by (iii) setting IOV to zero, (iv) summing variances of interindividual variability (IIV) and IOV into a single IIV term, or (v) re-estimating the model without IOV. The impact of varying IOV magnitudes (0-50%) and number of occasions/observations was explored. The approaches were compared with conventional weight-based dosing. Predictive performance was assessed with the prediction error percentiles.
resultsWhen IOV was lower than IIV, the accuracy was good for all approaches (50
conclusionsBased on the studied scenarios and theoretical expectations, the best approach to handle IOV in model-based dose individualization is to include IOV in the generation of the EBEs but exclude the portion of unexplained variability related to IOV in the individual parameters used to calculate the future dose.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.